Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05432193 · ClinicalTrials.gov registry record · Phase 1
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
A Phase 1 study, sponsored by POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT05432193 is a Phase 1 study that was terminated before completion, run by POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company. The registered enrollment target is 20 participants.
The verdict
NCT05432193, a Phase 1 study, was terminated before completion, sponsored by POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This Phase 1 study will evaluate the safety and tolerability of \[Ga-68\]-PNT6555 and \[Lu-177\]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.
Interventions
- DRUG [Ga-68]-PNT6555
- DRUG [Lu-177]-PNT6555
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-07-13 |
| Est. Completion | 2024-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05432193
The ClinicalTrials.gov registry entry for NCT05432193 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which [Ga-68]-PNT6555 is the first listed.
NCT05432193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05432193 about?
NCT05432193 is a clinical study titled "FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)". This Phase 1 study will evaluate the safety and tolerability of \[Ga-68\]-PNT6555 and \[Lu-177\]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.
What is the current status of trial NCT05432193?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2022-07-13. Estimated completion is 2024-10-02.
What interventions are being tested in trial NCT05432193?
The interventions under investigation include: [Ga-68]-PNT6555 (DRUG), [Lu-177]-PNT6555 (DRUG).
Who is sponsoring clinical trial NCT05432193?
This trial is sponsored by POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.